reports
Pharming Group reports first quarter 2025 financial results and provid...
Pharming Group reports first quarter 2025 financial results and provides business update First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product’s unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adju...
Pharming Group announces the 2025 Annual General Meeting of Shareholde...
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The Board of Directors has decide...
- Clement Genelot
Roche Bobois: Q1 affected by delivery delays
Q1 disappointed because of delayed deliveries in the US (customs slowdowns) and at Cuir Center (dockworker strikes), only pointing to a catch-up in coming months. Price adjustments have already been implemented to cope with tariffs and FX and we expect quantified EBITDA guidance alongside the H1 pu
Pharming Group announces upcoming presentations at the 2025 Annual Mee...
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3K...
- Jean-François Granjon
SCHP SECHE ENVIRONNEMENT
VAC PIERRE & VACANCES SA
NXI NEXITY SA CLASS A
MF WENDEL SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
STF STEF
ITP INTERPARFUMS
SWP SWORD GROUP SE
CGM CEGEDIM SA
VETO VETOQUINOL SA
MRN MERSEN SA
MTU MANITOU BF SA
FII LISI SA
LSS LECTRA SA
GBT GUERBET SA
CDA COMPAGNIE DES ALPES SA
ATE ALTEN SA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
HEIJM HEIJMANS N.V. CERT
MBWS
PAL MARIE BRIZARD WINE & SPIRITS SA
GNFT PALFINGER AG
SEFER GENFIT SA
LIGHT SERGEFERRARI GROUP SA
11B SIGNIFY NV
INSD 11 BIT STUDIOS S.A.
ALR VERIMATRIX SA
SPIE ALIOR BANK SA
LFDE SPIE SA
TEC LA FRANCAISE DE L'ENERGIE SA
FTG111 TECHNIPFMC PLC
TKO FLATEXDEGIRO AG
VOS TIKEHAU CAPITAL SCA
AGR VOSSLOH AG
RBO AGRANA BETEILIGUNGS-AG
ZEL ROCHE BOBOIS INTERNATIONAL SAS
WDP PHARMA MAR SA
FUR WAREHOUSES DE PAUW SCA
FUGRO NV
- Jeremy Garnier
- Jean-François Granjon
SCHP SECHE ENVIRONNEMENT
VAC PIERRE & VACANCES SA
NXI NEXITY SA CLASS A
MF WENDEL SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
STF STEF
ITP INTERPARFUMS
SWP SWORD GROUP SE
CGM CEGEDIM SA
VETO VETOQUINOL SA
MRN MERSEN SA
MTU MANITOU BF SA
FII LISI SA
LSS LECTRA SA
CDA COMPAGNIE DES ALPES SA
ATE ALTEN SA
XIOR XIOR STUDENT HOUSING N.V.
COFB COFINIMMO SA
SAVE SAVENCIA SA
HEIJM HEIJMANS N.V. CERT
MBWS
PAL MARIE BRIZARD WINE & SPIRITS SA
GNFT PALFINGER AG
SEFER GENFIT SA
LIGHT SERGEFERRARI GROUP SA
11B SIGNIFY NV
INSD 11 BIT STUDIOS S.A.
ALR VERIMATRIX SA
SPIE ALIOR BANK SA
LFDE SPIE SA
TEC LA FRANCAISE DE L'ENERGIE SA
FTG111 TECHNIPFMC PLC
TKO FLATEXDEGIRO AG
VOS TIKEHAU CAPITAL SCA
AGR VOSSLOH AG
RBO AGRANA BETEILIGUNGS-AG
ZEL ROCHE BOBOIS INTERNATIONAL SAS
WDP PHARMA MAR SA
FUR WAREHOUSES DE PAUW SCA
FUGRO NV
- Jeremy Garnier
Pharming receives positive recommendation from NICE for Joenja®▼(lenio...
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive f...
Pharming Group announces the filing of its 2024 Annual Report and Form...
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website. The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2024 Annual Report on Form 20-F can be found und...
- Clement Genelot
Roche Bobois: 2025 a year of recovery
Post-FY 2024, we have cut our estimates by 2% and our PT from EUR47 to EUR46. We see 2025 as a year of recovery for both revenues (set to rise >5%) and EBITDA (up 17% YoY) with consensus slightly conservative. The investment case remains untouched with MSD% sales CAGR, a margin accretive focus o
- Jerôme Bodin
- Thomas Zlowodzki
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
OSE OSE IMMUNOTHERAPEUTICS SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
HCO HIGHCO SA
PSM PROSIEBENSAT.1 MEDIA SE
IPH INNATE PHARMA SA CLASS A
NTG NETGEM SA
LNA LNA SANTE SA
GBT GUERBET SA
VOE VOESTALPINE AG
ALCAR CARMAT SA
ACX ACERINOX SA
TRI TRIGANO SA
FR VALEO SE
G24 SCOUT24 AG
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
QDT QUADIENT SA
POS PORR AG
NDA AURUBIS AG
CAI CA IMMOBILIEN ANLAGEN AG
CIE CIE AUTOMOTIVE S.A.
MONT MONTEA SCA
SLIGR SLIGRO FOOD GROUP N.V.
KTCG KAPSCH TRAFFICCOM
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SEFER SERGEFERRARI GROUP SA
ALBFR SIDETRADE SA
FYB FORMYCON AG
SMHN SUESS MICROTEC AG
FACC FACC AG
RACE FERRARI NV
RIO RIO TINTO PLC
BHP BHP GROUP LTD
PIRC PIRELLI & C. S.P.A.
JST JOST WERKE AG
AMAG AMAG AUSTRIA METALL AG
VOS VOSSLOH AG
UMI UMICORE
GEST GESTAMP AUTOMOCION S.A.
2CRSI 2CRSI SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
ALCUR ARCURE SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
FAST FASTNED
ALAFY AFYREN
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
LHYFE LHYFE S.A.
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
IOS IONOS GROUP SE
TUI TUI AG
DSFIR KONINKLIJKE DSM N.V.
R3NK RENK GROUP AG
ARVEN ARVERNE GROUP SA
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Jerôme Bodin
- Thomas Zlowodzki
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
OSE OSE IMMUNOTHERAPEUTICS SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
HCO HIGHCO SA
PSM PROSIEBENSAT.1 MEDIA SE
IPH INNATE PHARMA SA CLASS A
NTG NETGEM SA
LNA LNA SANTE SA
GBT GUERBET SA
VOE VOESTALPINE AG
ALCAR CARMAT SA
ACX ACERINOX SA
TRI TRIGANO SA
FR VALEO SE
G24 SCOUT24 AG
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
QDT QUADIENT SA
POS PORR AG
NDA AURUBIS AG
CAI CA IMMOBILIEN ANLAGEN AG
CIE CIE AUTOMOTIVE S.A.
MONT MONTEA SCA
SLIGR SLIGRO FOOD GROUP N.V.
KTCG KAPSCH TRAFFICCOM
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SEFER SERGEFERRARI GROUP SA
ALBFR SIDETRADE SA
FYB FORMYCON AG
SMHN SUESS MICROTEC AG
FACC FACC AG
RACE FERRARI NV
RIO RIO TINTO PLC
BHP BHP GROUP LTD
PIRC PIRELLI & C. S.P.A.
JST JOST WERKE AG
AMAG AMAG AUSTRIA METALL AG
VOS VOSSLOH AG
UMI UMICORE
GEST GESTAMP AUTOMOCION S.A.
2CRSI 2CRSI SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
ALCUR ARCURE SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
FAST FASTNED
ALAFY AFYREN
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
LHYFE LHYFE S.A.
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
IOS IONOS GROUP SE
TUI TUI AG
DSFIR KONINKLIJKE DSM N.V.
R3NK RENK GROUP AG
ARVEN ARVERNE GROUP SA
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Jeremy Garnier
- Jeremy Garnier
Pharming Group announces first patient dosed in Phase II clinical tria...
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) an...
Pharming Group reports fourth quarter and full year 2024 financial res...
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023Joenja® revenue increased by 147% to US$45.0 million in...
Pharming Group reports on results of the 2025 Extraordinary General Me...
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of...
Pharming Group to participate in March investor conference
Pharming Group to participate in March investor conference Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of March: 37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:30pm PT/21:30 CET. For more informati...
Pharming Group to report fourth quarter and full year 2024 financial r...
Pharming Group to report fourth quarter and full year 2024 financial results on March 13 Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025. Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 13, 2025. To participate in the conference call, please register in advance using the link below. Once registered, dial-in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.